Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population;Prevalencia y caracteriśticas del síndrome metabólico en la población hipertensa Española

Medicina Clinica

Volumn 126, Issue 11, 2006, Pages 406-409

  De La Sierra, Alejandro ^a   Romero, Ramón ^b   Bonet, Josep ^b   Pérez, Montserrat ^c   Loṕez, Juan S ^c   Ravella, Ramón ^c   Aguilera, María T ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Pharma Consult Services SA   (Spain)

^d Grupo Sanofi Aventis   (Spain)

Author keywords

Abdominal obesity; Diabetes; Dislipidemia; Hypertension; Metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; URIC ACID;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG TOLERANCE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREVALENCE; SPAIN; URIC ACID BLOOD LEVEL; ADULT; AGED; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SPAIN;

EID: 33646373691     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086123     Document Type: Article

References (25)

1. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905-12.
2. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk. The Framingham experience. Arch Intern Med. 2002;162:1967-72.
3. Reaven GM. Role of insulin resistence in human disease. Banting lecture 1988. Diabetes. 1988;37:1595-607.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-421.
5. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-8.
6. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation. 2004;109:433-8.
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
8. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109:42-6.
9. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004; 164:1066-76.
10. International Diabetes Federation. New diagnostic criteria for metabolic syndrome [accedido 13 Oct 2005]. Disponible en: www.idf.org/webcast/pdf
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings for the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
12. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome. Prevalence and associated risk factors findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
13. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110: 1245-50.
14. Álvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del sindrome metabolico en la Comunidad Canaria. Med Clin (Barc). 2003;120: 172-4.
15. Álvarez Cosmea A, López Fernández V, Suárez García S, Arias García T, Prieto Diáz MA, Díaz González L. Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS. Med Clin (Barc). 2005;124: 368-70.
16. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
17. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817-22.
18. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22:1991-8.
19. Rodilla E, García L, Merino C, Costa JA, Gonzalez C, Pascual JM. Importancia del síndrome metabolico en el control de la presión arterial y de la dislipemia. Med Clin (Barc). 2004;123:601-5.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.
21. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A0828.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
23. De Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents. Findings from the third National Health and Nutrition Examination Survey. Circulation. 2004;110:2494-7.
24. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
25. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm L, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-69.